Disclaimer: This article is intended solely for informational and educational purposes only. It does not constitute medical advice.
Neuraxial anesthesia is traditionally achieved with local anesthetics such as bupivacaine, lidocaine, and ropivacaine, which produce reversible sensory and motor blockade by inhibiting voltage-gated sodium channels. However, certain clinical circumstances, including allergies, local anesthetic systemic toxicity, drug shortages, or the need to prolong analgesia, have prompted interest in alternative neuraxial agents. Although no currently available medication fully replaces the pharmacologic properties of local anesthetics, several drugs administered intrathecally or epidurally can provide analgesia or augment anesthetic effects through different mechanisms. These alternatives are generally considered adjuncts rather than true substitutes for local anesthetics and should be used in neuraxial anesthesia only after careful consideration of their efficacy, safety profile, and regulatory approval status (1).
Neuraxial opioids represent the most established alternative class for spinal and epidural analgesia. Lipophilic opioids such as fentanyl and sufentanil provide rapid onset of analgesia with limited upward spread, making them useful for labor analgesia and as supplements during surgical anesthesia. Hydrophilic morphine produces prolonged postoperative analgesia because of its slower cerebrospinal fluid clearance, but it can cause delayed respiratory depression, so appropriate monitoring is required. Although neuraxial opioids provide effective spinal analgesia, they do not produce the dense sensory, motor, or sympathetic blockade necessary for most surgical procedures. Consequently, they are generally used as adjuncts.¹ Nevertheless, they remain valuable when sensory analgesia is desired while preserving motor function or when local anesthetic doses must be minimized (1).
In addition to having established uses in anesthesia and analgesia, alpha-2 adrenergic agonists may be used as alternatives to local anesthetics in neuraxial anesthesia. Clonidine and dexmedetomidine act through presynaptic and postsynaptic alpha-2 receptors within the dorsal horn of the spinal cord, reducing neurotransmitter release and enhancing descending inhibitory pain pathways. Clinical studies have demonstrated that these medications prolong sensory block, improve postoperative analgesia, and reduce opioid consumption when administered intrathecally or epidurally. Dexmedetomidine has attracted increasing attention because it provides longer-lasting analgesia than clonidine in many studies while producing relatively stable hemodynamic effects at appropriate doses. However, hypotension, bradycardia, and sedation remain important dose-dependent adverse effects, limiting their role as primary neuraxial anesthetics (2).
Other investigational neuraxial agents include ketamine, neostigmine, magnesium sulfate, and midazolam. Ketamine acts primarily through antagonism of N-methyl-D-aspartate (NMDA) receptors, thereby reducing central sensitization, a process in which repeated nociceptive input increases spinal cord excitability and amplifies postoperative pain. Despite its potential analgesic benefits, concerns regarding neurotoxicity and limited evidence supporting its safety have restricted the routine use of intrathecal ketamine. Neostigmine enhances spinal cholinergic transmission by inhibiting acetylcholinesterase and can produce analgesia without significant respiratory depression, although its clinical utility is limited by a high incidence of nausea and vomiting.
Magnesium sulfate has also been investigated as an intrathecal adjuvant because of its analgesic properties, although evidence supporting its efficacy remains inconsistent. Similarly, intrathecal midazolam has demonstrated antinociceptive effects through modulation of γ-aminobutyric acid (GABA)-mediated pathways, but concerns regarding long-term neurologic safety have precluded its routine clinical use. Despite encouraging findings in selected studies, evidence supporting the routine clinical use of these agents remains insufficient because of inconsistent efficacy and unresolved safety concerns (3).
Current evidence suggests that alternatives to local anesthetics in neuraxial anesthesia are best regarded as adjuncts rather than replacements. Although these agents may prolong analgesia, enhance block quality, or reduce perioperative opioid requirements, most are most effective when used in combination with conventional local anesthetics. Their use should be carefully considered only in cases of clear need, taking into account patient characteristics, procedural requirements, and institutional protocols while recognizing that many neuraxial applications remain off-label. Ongoing research continues to refine dosing strategies and evaluate novel agents that optimize analgesia while minimizing adverse effects.
References
- Schug SA, Saunders D, Kurowski I, Paech MJ. Neuraxial drug administration: a review of treatment options for anaesthesia and analgesia. CNS Drugs. 2006;20(11):917-933. doi:10.2165/00023210-200620110-00005
- Schwartz RH, Hernandez S, Noor N, et al. A Comprehensive Review of the Use of Alpha 2 Agonists in Spinal Anesthetics. Pain Physician. 2022;25(2):E193-E201.
- Axelsson K, Gupta A. Local anaesthetic adjuvants: neuraxial versus peripheral nerve block. Curr Opin Anaesthesiol. 2009;22(5):649-654. doi:10.1097/ACO.0b013e32832ee847